EGFR and non-small cell lung carcinoma: Given the encouraging results of a phase II study of dacomitinib in the first-line setting [24], ARCHER 1050, a randomized, open-label phase III study of dacomitinib versus gefitinib, was conducted in treatment-naive patients with EGFR mutation–positive advanced NSCLC.